A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (NCT04432584)

🧪 Interventions in This Study

• Crovalimab (DRUG)
• Eculizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (80 Sites)

Showing the first 25 of 80 sites.

• Carolinas Healthcare System — Charlotte, North Carolina
• Nationwide Children's Hospital — Columbus, Ohio
• Cliniques Universitaires Saint-Luc — Brussels,
• AZ Delta Campus Westlaan — Roeselare,
• Chronos Pesquisa Clinica — Taguatinga, Federal District
• Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
• Hospital de Clínicas de Porto Alegre X — Porto Alegre, Rio Grande do Sul
• Instituto Joinvilense de Hematologia E Oncologia — Joinville, Santa Catarina
• Hospital das Clínicas FMRP-USP — Ribeirão Preto, São Paulo
• *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia — Santo André, São Paulo
• Hospital Sírio-Libanês — São Paulo, São Paulo
• Hospital Paulistano — São Paulo, São Paulo
• Beneficencia Portuguesa de Sao Paulo — São Paulo,
• Ustav hematologie a krevni transfuze — Prague,
• North Estonia Medical Centre Foundation — Tallinn,
• Hopital Claude Huriez - CHU Lille — Lille,
• Institut Paoli Calmette — Marseille,
• Universitaetsklinikum Aachen AOeR — Aachen,
• ELBLANDKLINIKUM Riesa — Riesa,
• General Hospital of Athens LAIKO — Athens,
• Attikon University General Hospital — Athens,
• Prince of Wales Hospital — Hong Kong,
• Semmelweis Egyetem — Budapest,
• St James's Hospital — Dublin,
• Azienda Unita Sanitaria Locale- Ravenna — Ravenna, Emilia-Romagna

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Paroxysmal Nocturnal Hemoglobinuria

• Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data — Boston, Massachusetts
• A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors — Ciudad Autonoma Buenos Aires,
• Long-term Safety of Danicopan: IPIG Registry-based Cohort Study — Boston, Massachusetts
• A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH — Los Angeles, California
• Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria — Duarte, California
• A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment — Whittier, California

Explore by condition: All Paroxysmal Nocturnal Hemoglobinuria clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.